Briquilimab Shows Positive Results in ETESIAN Phase 1b Study, Asthma Treatment Advances

Jasper Therapeutics reported positive preliminary clinical data from its ETESIAN Phase 1b study of subcutaneous briquilimab in adult participants with allergic asthma. A single subcutaneous dose of 180mg briquilimab demonstrated substantial reductions in sputum eosinophils and improvements in FEV1. Briquilimab was well tolerated and showed a favorable safety profile. Jasper also concluded that the anomalous lack of clinical response in the BEACON study was due to patient selection issues, not drug product issues.